DUBLIN, June 9, 2022 /PRNewswire/ — The “Human Microbiome Market: Focus on Therapeutics, Diagnostics and Fecal Microbiota Therapy: Distribution by Type of Molecule, Type of Product, Target Indication, Therapeutic Areas, Supply Channels and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035” report has been added to ResearchAndMarkets.com’s offering.
The ‘The Human Microbiome Market (4th Edition), 2022-2035’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of microbiome-based therapeutics, diagnostics and FMTs, over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.
One of the key objectives of the report was to estimate the existing market size and future growth opportunity for microbiome therapeutics, diagnostics and FMTs, over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends of the sales, of approved / late stage (estimated) microbiome therapeutics, diagnostic products and FMTs.
The report also features the likely distribution of the current and forecasted opportunity within microbiome therapeutics market across type of molecule (small molecule and biologics), type of product (probiotic and other drug), target indication (graft versus host disease, necrotizing enterocolitis, primary hyperoxaluria and recurrent CDI ), therapeutic area (digestive and gastrointestinal disorders, infectious diseases and rare disorders), route of administration (oral and rectal), key geographical regions.
In order to account for the uncertainties associated with the growth of microbiome market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The ongoing research efforts, focused on targeting and modulating microbiome, have led to the development of treatment options for more than 25 indications. In addition, probiotic therapies with live biotherapeutic products (microbes) are considered to be the most advanced microbiome-based therapies for restoring bacterial symbiosis.
At present, fecal microbiota transplantation (FMT) involving the transfer of complete microbial community from a healthy donor’s feces to recipient via oral (in form of a capsule) or rectal (enema and colonoscopy) is the only FDA-approved microbiome therapy, for the treatment of recurrent CDI. However, several players are engaged in developing prescription drugs modulating human microbiome for the treatment of various gastrointestinal and non-gastrointestinal disorders as well.
Further, a number of microbiome diagnostic and screening / profiling tests are commercially available for the detection of different microbiome-related diseases. It is worth mentioning that, owing to the rising interest, a number of start-ups / small firms have established in the past few years and the contributions of big pharma players have fueled the overall growth in this domain.
Driven by increasing prevalence of disease indications, promising therapeutic potential of microbiome-based therapies, encouraging clinical trial results and financial support from the investors, the human microbiome therapeutics and diagnostics market is likely to witness substantial growth in the mid to long-term.
The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company / organization names):
Lee Jones (President and Chief Executive Officer, Rebiotix)
Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)
Colleen Cutcliffe (Co-founder and Chief Executive Officer, Pendulum Therapeutics)
Nikole Kimes (Co-founder and Chief Executive Officer, Siolta Therapeutics)
James Burges (Co-founder and Vice President of Innovation, Finch Therapeutics)
JP Benya (Vice President, Operations, Flame Biosciences)
Debbie Pinkston (Former Vice President, Sales and Business Development, List Biological Laboratories)
Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics)
Mark Heiman (Chief Scientific Officer and Vice President, Research, Scioto Biosciences)
Alexander Segal (Founder, Stealth Startup)
Assaf Oron (Chief Business Officer, BiomX)
Pierre-Alain Bandinelli (Chief Strategy Officer, Da Volterra)
Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)
Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)
Nicholas Monsul (Co-founder and Chairman, Quorum Innovations)
Charlie Badham (Senior Manager, Corporate Development, 4D Pharma)
Key Questions Answered
Who are the leading players engaged in the development of microbiome therapeutics?
Which are the key drugs being developed across various stages of development?
Which companies are actively involved in conducting clinical trials for microbiome therapeutics and FMTs?
Who are the leading players engaged in the development of microbiome diagnostics and screening / profiling tests?
What kind of partnership models are commonly adopted by industry stakeholders?
Who are the key investors active in the field of human microbiome therapeutics and diagnostics?
What are the different initiatives undertaken by big pharma players for the development of human microbiome therapeutics in the recent past?
What is the role of various start-ups engaged in the developing human microbiome therapeutics?
Which are the most commonly targeted therapeutic indications for microbiome therapeutics are being developed?
What are the various steps involved in the manufacturing of microbiome therapeutics and what are the key considerations for selecting a CMO / CRO?
What are the various algorithms / tools used to analyze data generated from microbiome research?
How is the current and future opportunity, related to microbiome therapeutics, diagnostics and FMT likely to be distributed across key market segments?
What are the various non-pharma applications of microbiome products?
Key Topics Covered:
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Microbiota and Microbiome
3.3. Overview of Gut Flora
3.4. The Microbiome and Associated Diseases
3.5. Impact of Microbiota on Drug Pharmacokinetics
3.6. Impact of Microbiota on Therapeutic Outcomes
3.7. Microbiome Therapeutics
3.8. The Human Microbiome Project (HMP)
3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
3.10. Key Challenges Associated with the Development of Microbiome Therapeutics
3.11. Future Perspectives
4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Microbiome Therapeutics: Clinical Pipeline
4.3. Microbiome Therapeutics: Preclinical Pipeline
4.4. Microbiome Therapeutics: List of Drug Developers
5. MICROBIOME THERAPEUTICS: COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. Microbiome Therapeutics Developers: Companies with Candidate(s) in Highest Phase of Development
5.3. Finch Therapeutics
5.4. Infant Bacterial Therapeutics
5.5. MaaT Pharma
5.6. OxThera
5.7. Rebiotix (acquired by Ferring Pharmaceuticals)
5.8. Seres Therapeutics
5.9. Microbiome Therapeutics Developers: Companies with Maximum Number of Therapeutic Programs
5.10. 4D Pharma
5.11. Biosortia Pharmaceuticals
5.12. Qu Biologics
5.13. Servatus
6. CLINICAL TRIAL ANALYSIS: HUMAN MICROBIOME THERAPEUTICS
6.1. Chapter Overview
6.2. Human Microbiome Therapeutics: List of Clinical Trials
7. MICROBIOME DIAGNOSTICS AND SCREENING / PROFILING TESTS: MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Overview of Microbiome Diagnostics and Screening / Profiling Tests
7.3. Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Under Development Products
7.4. Microbiome Diagnostic and Screening / Profiling Tests Providers
8. MICROBIOME DIAGNOSTIC AND SCREENING / PROFILING TEST PROVIDERS: COMPANY PROFILES
8.1. Chapter Overview
8.2. Shoreline Biome
8.3. DNA Genotek
8.4. Invivo Healthcare
8.5. GoodGut
8.6. BiomeDx
9. FECAL MICROBIOTA THERAPY (FMT)
9.1. Chapter Overview
9.2. Introduction to Fecal Microbiota Therapy
9.3. Historical Overview
9.4. Fecal Microbiota Therapy: Procedure and Clinical Relevance
9.5. Regulatory Guidelines Related to Fecal Microbiota Therapy
9.6. Insurance Coverage for Fecal Microbota Therapy
9.7. Fecal Microbiota Therapy: Marketed and Development Pipeline
9.8. Fecal Microbiota Therapy: List of Developers
9.9. Stool Banks
10. CLINICAL TRIALS ANALYSIS: FECAL MICROBIOTA THERAPY
10.1. Chapter Overview
10.2. List of Clinical Trials
11. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX
11.1. Chapter Overview
11.2. AC Matrix: An Overview
11.3. AC Matrix: Analytical Methodology
11.4. AC Matrix: Plotting the Information
11.5. AC Matrix: Analyzing the Data
11.6. Concluding Remarks
12. MICROBIOME RELATED INITIATIVES OF BIG PHARMA PLAYERS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Initiatives of Big Pharma Players
12.4. Benchmarking Analysis of Big Pharma Players
13. START-UP HEALTH INDEXING
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Benchmarking of Start-ups
14. KEY THERAPEUTIC AREAS
14.1. Chapter Overview
14.2. Metabolic Disorders
14.3. Digestive and Gastrointestinal Disorders
14.4. Oncological Indications
14.5. Dermatological Disorders
14.6. Infectious Diseases
15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. Human Microbiome: List of Partnerships and Collaborations
15.4. Analysis by Year of Partnership
15.5. Analysis by Type of Partnership
15.6. Analysis by Year and Type of Partnership
15.7. Analysis by Type of Product
15.8. Analysis by Target Indication
15.9. Analysis by Therapeutic Area
15.10. Analysis by Type of Company
15.11. Analysis by Type of Partner
15.12. Most Active Players: Analysis by Number of Partnerships
15.13. Intercontinental and Intracontinental Agreements
16. FUNDING AND INVESTMENT ANALYSIS
16.1. Chapter Overview
16.2. Types of Funding
16.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments
17. CASE STUDY: CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS AND LIVE BIOTHERAPEUTICS
17.1. Chapter Overview
17.2. Manufacturing Microbiome Therapeutics
17.3. Key Considerations for Selecting a CMO / CRO Partner
18. BIG DATA AND MICROBIOME THERAPEUTICS
18.1. Chapter Overview
18.2. Introduction to Big Data
18.3. Internet of Things (IoT)
18.4. Growing Interest in Big Data: Google Trends Analysis
18.5. Key Application Areas
18.6. Big Data in Microbiome Research
18.7. Big Data Services for Microbiome Research: List of Companies
18.8. Big Data Services for Microbiome Research: Profiles of Key Players
19. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
19.1. Chapter Overview
19.2. Key Assumptions
19.3. Forecast Methodology
19.4. Global Microbiome Therapeutics Market, 2022-2035
19.5. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2022-2035
20. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Key Assumptions
20.3 Forecast Methodology
20.4. Global Microbiome Diagnostics Market, 2022-2035
20.5. Microbiome Diagnostics Market: Distribution by Target Indication, 2022-2035
20.6. Microbiome Diagnostics Market: Distribution by Therapeutic Area, 2022-2035
20.7. Microbiome Diagnostics Market: Distribution by Supply Channel, 2022-2035
20.8. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2022-2035
21. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS
21.1. Chapter Overview
21.2. Key Assumptions
21.3. Forecast Methodology
21.4. Overall FMT Market, 2022-2035
21.5. Overall Microbiome Market by Product Offerings, 2022-2035
22. CASE STUDY: MICROBIOME-BASED PRODUCTS IN NON-PHARMACEUTICAL INDUSTRIES
22.1. Chapter Overview
22.2. List of Microbiome Products in Non-Pharmaceutical Industry
22.3. Applications of Microbiome Based Products in Agriculture Industry
22.4. Future Perspectives
23. CONCLUDING REMARKS
24. EXECUTIVE INSIGHTS
24.1 Chapter Overview
24.2. Rebiotix
24.3. S-Biomedic
24.4. Pendulum Therpaeutics
24.5. Siolta Therapeutics
24.6. Finch Therapeutics
24.7 Flame Biociences
24.8. List Biological Laboratories
24.9. Metabiomics
24.10. Scioto Biosciences
24.11. Stealth Startup
24.12. BiomX
24.13. Da Volterra
24.14. Chung Mei Pharmaceutical
24.15. Pacific Northwest National Laboratories
24.16. Quorum Innovations
24.17. 4D Pharma
25. APPENDIX I: TABULATED DATA
26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/fsj5me
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-human-microbiome-market-research-report-2022-current-market-landscape-likely-adoption-of-microbiome-based-therapeutics-diagnostics-and-fmts-over-the-next-decade-301564902.html
SOURCE Research and Markets
After climbing more than 60% this year, energy stocks still have room to run. Six picks in the industry’s most promising areas.
The relaunched restaurants were accompanied by a marketing blitz aimed at convincing locals that the new chain’s burgers are as good as the American version.
Coinbase Global Inc. has had a rough stretch lately, as plunging prices for cryptocurrencies have dampened trading interest and prompted the company to curtail rapid hiring plans.
The golden arches are gone, the filet-of-fish is simply a fish burger. The Big Mac has left Russia. A new era for Russia's fast-food and economic scene dawned on Sunday as McDonald's restaurants flung open their doors in Moscow under new Russian ownership and with the new name, which translates as "Tasty and that's it".
Following the world's greatest investor can pay handsome rewards during tough market conditions.
High oil prices are usually blamed for record gas prices, but there's also a refinery shortage. More oil's meaningless if we can't convert it to gas.
No two ways about it: It's been a challenging year on Wall Street. Since the curtain opened on 2022, the iconic Dow Jones Industrial Average and broad-based S&P 500 have both fallen by a double-digit percentage. Meanwhile, the growth stock-fueled Nasdaq Composite (NASDAQINDEX: ^IXIC) has declined by a peak of 31% since hitting its record-closing high in November.
Start saving up money because a bad recession could be nearing, warns one economic expert.
(Bloomberg) — For all that the slump in technology stocks has headlined a treacherous year for global equity markets, there’s one sector that’s faring even worse.Most Read from BloombergUS Lifts Covid-19 Test Requirement for International TravelTreasuries Dare Fed to Step Up Hikes or Risk Inflation DefeatTrump’s Air Force One Deal Pains the Pentagon, Not Just BoeingRetailers Should Heed Target’s Cautionary TaleUS Inflation Quickens to 40-Year High, Pressuring Fed and BidenThe MSCI World Retaili
More than a century ago, Henry Ford transformed the way people traveled from one place to another. The Blue Oval has since become an iconic brand with a loyal customer base. The big question today is, can Ford (NYSE: F) stay as relevant for another century?
LOS ANGELES (Reuters) -U.S. President Joe Biden on Friday accused the U.S. oil industry, and Exxon Mobil Corp in particular, of capitalizing on a supply shortage to fatten profits after a report showed inflation surging to a new 40-year record. U.S. consumer inflation accelerated in May https://www.reuters.com/markets/us/soaring-gasoline-food-prices-boost-us-consumer-inflation-may-2022-06-10 as gasoline prices hit a record high and the cost of food soared, leading to the largest annual increase in four decades. Biden, who came into office vowing to reduce U.S. dependence on fossil fuels, said on Friday he was hoping to speed up oil production, which is expected to hit record highs in the United States next year.
The money guru says too many people retire only with enough savings to last a few years.
See who joins Meta and GOOGL on this screen of Warren Buffett stocks based on the investing strategy of Berkshire Hathaway's CEO.
The Facebook parent’s lawyers have been investigating outgoing COO Sheryl Sandberg’s use of corporate resources for personal projects going back several years, people familiar with the matter say.
The warehouse club offers savings of about 37 cents a gallon at a time of record prices at the pump.
President Biden took a swipe at Exxon Mobil but other companies make far more. On profits, Apple is by far the champ, followed by Alphabet.
(Bloomberg) — Women at Oracle Corp. suing over alleged pay disparities took a big step backward, while more than 15,000 female workers at Google crossed the finish line.Most Read from BloombergUS Lifts Covid-19 Test Requirement for International TravelTreasuries Dare Fed to Step Up Hikes or Risk Inflation DefeatTrump’s Air Force One Deal Pains the Pentagon, Not Just BoeingRetailers Should Heed Target’s Cautionary TaleUS Inflation Quickens to 40-Year High, Pressuring Fed and BidenUnder a judge’s
(Bloomberg) — Google, Facebook and Microsoft Corp. — three of the world’s biggest corporate buyers of clean power — are sounding the alarm that a nearly $4 billion, Warren Buffett-backed renewable-energy project proposed in Iowa isn’t necessarily in the best interest of customers, including them.Most Read from BloombergUS Lifts Covid-19 Test Requirement for International TravelTreasuries Dare Fed to Step Up Hikes or Risk Inflation DefeatTrump’s Air Force One Deal Pains the Pentagon, Not Just Bo
American Apparel CEO Stephen Lamar joins Yahoo Finance Live to discuss the outlook for the retail sector as consumer sentiment plummets and how supply chain issues are exacerbating problems.
Global demand for natural gas is expected to rise over the next couple decades, and this pipeline specialist is ready to provide it.
